放射组学和 PD-L1 表达预测头颈部鳞状细胞癌患者免疫治疗的获益。
Radiomics and PD-L1 expression predict immunotherapy benefits in patients with head and neck squamous cell carcinoma.
机构信息
Department of Radiology & Research Institute of Radiological Science & Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Korea.
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
Future Oncol. 2024;20(36):2869-2878. doi: 10.1080/14796694.2024.2342226. Epub 2024 May 15.
To evaluate the performance of MRI-derived radiomic risk score (RRS) and PD-L1 expression to predict overall survival (OS) and progression-free survival (PFS) of patients with recurrent head and neck squamous cell carcinoma receiving nivolumab therapy. Three hundred forty radiomic features from pretreatment MRI were used to construct the RRS. The integrated area under the receiver operating characteristic curve (iAUC) was calculated to evaluate the performance of the RRS and PD-L1. The RRS showed iAUCs of 0.69 and 0.57 for OS and PFS, respectively. PD-L1 expression showed iAUCs of 0.61 and 0.62 for OS and PFS, respectively. RRS and PD-L1 potentially predict the OS and PFS of patients with recurrent head and neck squamous cell carcinoma receiving nivolumab therapy.
评估 MRI 衍生的放射组学风险评分（RRS）和 PD-L1 表达对接受纳武利尤单抗治疗的复发性头颈部鳞状细胞癌患者总生存期（OS）和无进展生存期（PFS）的预测性能。从预处理 MRI 中提取 340 个放射组学特征来构建 RRS。计算综合受试者工作特征曲线下面积（iAUC）来评估 RRS 和 PD-L1 的性能。RRS 对 OS 和 PFS 的 iAUC 分别为 0.69 和 0.57。PD-L1 表达对 OS 和 PFS 的 iAUC 分别为 0.61 和 0.62。RRS 和 PD-L1 可能预测接受纳武利尤单抗治疗的复发性头颈部鳞状细胞癌患者的 OS 和 PFS。
Zotero 插件